CN112014567B - 超敏c反应蛋白测定试剂盒 - Google Patents
超敏c反应蛋白测定试剂盒 Download PDFInfo
- Publication number
- CN112014567B CN112014567B CN202010840493.5A CN202010840493A CN112014567B CN 112014567 B CN112014567 B CN 112014567B CN 202010840493 A CN202010840493 A CN 202010840493A CN 112014567 B CN112014567 B CN 112014567B
- Authority
- CN
- China
- Prior art keywords
- parts
- kit
- hypersensitive
- sodium
- sample diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 title claims description 19
- 108090000623 proteins and genes Proteins 0.000 title claims description 19
- 239000003085 diluting agent Substances 0.000 claims abstract description 43
- OOCCDEMITAIZTP-QPJJXVBHSA-N (E)-cinnamyl alcohol Chemical compound OC\C=C\C1=CC=CC=C1 OOCCDEMITAIZTP-QPJJXVBHSA-N 0.000 claims abstract description 30
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims abstract description 30
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims abstract description 15
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 15
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 15
- OOCCDEMITAIZTP-UHFFFAOYSA-N allylic benzylic alcohol Natural products OCC=CC1=CC=CC=C1 OOCCDEMITAIZTP-UHFFFAOYSA-N 0.000 claims abstract description 15
- FRHBOQMZUOWXQL-UHFFFAOYSA-L ammonium ferric citrate Chemical compound [NH4+].[Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FRHBOQMZUOWXQL-UHFFFAOYSA-L 0.000 claims abstract description 15
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 15
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims abstract description 15
- 229960004419 dimethyl fumarate Drugs 0.000 claims abstract description 15
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims abstract description 15
- 229960004642 ferric ammonium citrate Drugs 0.000 claims abstract description 15
- 239000004313 iron ammonium citrate Substances 0.000 claims abstract description 15
- 235000000011 iron ammonium citrate Nutrition 0.000 claims abstract description 15
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims abstract description 15
- 239000011976 maleic acid Substances 0.000 claims abstract description 15
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 claims abstract description 15
- 239000001472 potassium tartrate Substances 0.000 claims abstract description 15
- 229940111695 potassium tartrate Drugs 0.000 claims abstract description 15
- 235000011005 potassium tartrates Nutrition 0.000 claims abstract description 15
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 15
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 15
- 235000010265 sodium sulphite Nutrition 0.000 claims abstract description 15
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 claims abstract description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 claims description 18
- 108090000790 Enzymes Proteins 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 claims description 16
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 239000012089 stop solution Substances 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 claims description 8
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 8
- 229940043370 chrysin Drugs 0.000 claims description 8
- 235000015838 chrysin Nutrition 0.000 claims description 8
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 claims description 7
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000230 xanthan gum Substances 0.000 claims description 7
- 229920001285 xanthan gum Polymers 0.000 claims description 7
- 229940082509 xanthan gum Drugs 0.000 claims description 7
- 235000010493 xanthan gum Nutrition 0.000 claims description 7
- 108010074051 C-Reactive Protein Proteins 0.000 abstract description 27
- 102100032752 C-reactive protein Human genes 0.000 abstract description 27
- 238000001514 detection method Methods 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 6
- 230000004044 response Effects 0.000 abstract description 5
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 229940098895 maleic acid Drugs 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033654 Pancreatitis necrotising Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/067—Pancreatitis or colitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明提供了一种超敏C反应蛋白测定试剂盒。该技术方案对样品稀释液的成分进行了集中改进，采用硝酸铵、亚硫酸钠、正丙醇钠、乙二胺四乙酸二钠、顺丁烯二酸、富马酸二甲酯、羧甲基纤维素钠、酒石酸钾、柠檬酸铁铵、肉桂醇以特定比例复配，所形成的稀释液对样品具有良好的分散效果，同时可改善检测过程的灵敏性。实验结果表明，本发明的检测精度更高，响应速度更快，可检出的最低浓度得到降低，具有良好的使用效果。本发明以创新性的技术改进实现了良好的技术效果，其成本较低、易于实现，具有突出的应用前景。
Description
技术领域
本发明涉及医学检测技术领域，具体涉及一种超敏C反应蛋白测定试剂盒。
背景技术
C反应蛋白(C-reactive protein，CRP)是指在机体受到感染或组织损伤时血浆中一些急剧上升的蛋白质(急性蛋白)。CRP可以激活补体和加强吞噬细胞的吞噬而起调理作用，从而清除入侵机体的病原微生物和损伤、坏死、凋亡的组织细胞，在机体的天然免疫过程中发挥重要的保护作用。
CRP不仅是一种非特异的炎症标志物，其本身直接参与了炎症与动脉粥样硬化等心血管疾病，并且是心血管疾病最强有力的预示因子与危险因子。CRP与补体Clq及FcTR的相互作用使其表现出很多生物活性，包括宿主对感染的防御反应、对炎症反应的吞噬作用和调节作用等。与受损细胞、凋亡细胞及核抗原的结合，使其在自身免疫病方面也起着重要作用
CRP测定具有重要的临床意义。
(1)各种急性炎症、组织损伤、心肌梗死、手术创伤、放射性损伤等疾病发作后数小时迅速升高，并有成倍增长之势。病变好转时，又迅速降至正常，其升高幅度与感染的程度呈正相关。手术后患者CRP升高，术后7～10天CRP水平应下降，如CRP不降低或再次升高，提示可能并发感染或血栓栓塞。
(2)CRP与其他炎症因子,如白细胞总数、红细胞沉降率和多形核白细胞等具有密切相关性。又与WBC存在正相关。在炎症反应中起着积极作用，使人体具有非特异性抵抗力。在患者疾病发作时，可早于WBC而上升，恢复正常也很快，故具有极高的敏感性。
(3)帮助辨别呼吸道感染类型。CRP可用于细菌和病毒感染的鉴别诊断：细菌感染时，CRP水平升高；而病毒感染时，CRP不升高或轻度升高，因此CRP值可以帮助医生辨别呼吸道感染的类型，有针对性的给予药物和治疗。
(4)恶性肿瘤患者CRP都升高，如CRP与AFP的联合检测，可用于肝癌与肝脏良性疾病的鉴别诊断，应用于肝癌疗效及预后的判断。手术前CRP上升，手术后则下降，且其反应不受放疗、化疗和皮质激素治疗的影响，有助于评估肿瘤的进程。
(5)评估急性胰腺炎的严重程度，当CRP高于250mg/L时，则提示为广泛坏死性胰腺炎。
(6)用超敏乳胶增强法测CRP，能提高测定的敏感性，可用于冠心病和心梗危险性的预测。
由此可见，对C反应蛋白的测定具有重要的临床意义。目前，C反应蛋白可采用成品试剂盒快捷的予以测定，但常规C反应蛋白测定试剂盒的响应速度不够灵敏，导致检出精度较低，耗时较长，整体检测效率有待提升。
发明内容
本发明旨在针对现有技术的技术缺陷，提供一种超敏C反应蛋白测定试剂盒，以解决现有技术中，常规C反应蛋白测定试剂盒灵敏性较低的技术问题。
为实现以上技术目的，本发明采用以下技术方案：
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液包括以下重量份的成分：硝酸铵2～3份，亚硫酸钠1～2份，正丙醇钠0.5～1份，乙二胺四乙酸二钠0.8～1.2份，顺丁烯二酸0.8～1.4份，富马酸二甲酯2～3份，羧甲基纤维素钠1～2份，酒石酸钾2～3份，柠檬酸铁铵0.5～1份，肉桂醇1～2份。
作为优选，所述样品稀释液还包括1～2重量份的高良姜素。
作为优选，所述样品稀释液还包括1～2重量份的白杨素。
作为优选，所述样品稀释液还包括1～2重量份的黄原胶。
作为优选，所述样品稀释液还包括1～2重量份的N-甲基吡咯烷酮。
作为优选，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份。
作为优选，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，高良姜素1.5份，白杨素1.4份，黄原胶1.6份，N-甲基吡咯烷酮1.7份。
本发明提供了一种超敏C反应蛋白测定试剂盒。该技术方案对样品稀释液的成分进行了集中改进，采用硝酸铵、亚硫酸钠、正丙醇钠、乙二胺四乙酸二钠、顺丁烯二酸、富马酸二甲酯、羧甲基纤维素钠、酒石酸钾、柠檬酸铁铵、肉桂醇以特定比例复配，所形成的稀释液对样品具有良好的分散效果，同时可改善检测过程的灵敏性。实验结果表明，本发明的检测精度更高，响应速度更快，可检出的最低浓度得到降低，具有良好的使用效果。本发明以创新性的技术改进实现了良好的技术效果，其成本较低、易于实现，具有突出的应用前景。
具体实施方式
以下将对本发明的具体实施方式进行详细描述。为了避免过多不必要的细节，在以下实施例中对属于公知的结构或功能将不进行详细描述。以下实施例中所使用的近似性语言可用于定量表述，表明在不改变基本功能的情况下可允许数量有一定的变动。除有定义外，以下实施例中所用的技术和科学术语具有与本发明所属领域技术人员普遍理解的相同含义。
实施例1
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，高良姜素1.5份，白杨素1.4份，黄原胶1.6份，N-甲基吡咯烷酮1.7份。
实施例2
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份。
实施例3
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2份，亚硫酸钠1份，正丙醇钠0.5份，乙二胺四乙酸二钠0.8份，顺丁烯二酸0.8份，富马酸二甲酯2份，羧甲基纤维素钠1份，酒石酸钾2份，柠檬酸铁铵0.5份，肉桂醇1份。
实施例4
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵3份，亚硫酸钠2份，正丙醇钠1份，乙二胺四乙酸二钠1.2份，顺丁烯二酸1.4份，富马酸二甲酯3份，羧甲基纤维素钠2份，酒石酸钾3份，柠檬酸铁铵1份，肉桂醇2份。
实施例5
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，高良姜素1份，白杨素1份，黄原胶1份，N-甲基吡咯烷酮1份。
实施例6
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，高良姜素2份，白杨素2份，黄原胶2份，N-甲基吡咯烷酮2份。
实施例7
超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其中，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，白杨素1.8份，N-甲基吡咯烷酮1.1份。
以上对本发明的实施例进行了详细说明，但所述内容仅为本发明的较佳实施例，并不用以限制本发明。凡在本发明的申请范围内所做的任何修改、等同替换和改进等，均应包含在本发明的保护范围之内。
Claims (7)
1.超敏C反应蛋白测定试剂盒，包括酶标包被板，标准品，标准品稀释液，酶标试剂，样品稀释液，第一显色剂，第二显色剂，终止液，洗涤液；其特征在于，所述样品稀释液包括以下重量份的成分：硝酸铵2～3份，亚硫酸钠1～2份，正丙醇钠0.5～1份，乙二胺四乙酸二钠0.8～1.2份，顺丁烯二酸0.8～1.4份，富马酸二甲酯2～3份，羧甲基纤维素钠1～2份，酒石酸钾2～3份，柠檬酸铁铵0.5～1份，肉桂醇1～2份。
2.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液还包括1～2重量份的高良姜素。
3.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液还包括1～2重量份的白杨素。
4.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液还包括1～2重量份的黄原胶。
5.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液还包括1～2重量份的N-甲基吡咯烷酮。
6.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份。
7.根据权利要求1所述的超敏C反应蛋白测定试剂盒，其特征在于，所述样品稀释液由以下重量份的成分组成：硝酸铵2.5份，亚硫酸钠1.5份，正丙醇钠0.7份，乙二胺四乙酸二钠1份，顺丁烯二酸1.1份，富马酸二甲酯2.5份，羧甲基纤维素钠1.5份，酒石酸钾2.5份，柠檬酸铁铵0.8份，肉桂醇1.6份，高良姜素1.5份，白杨素1.4份，黄原胶1.6份，N-甲基吡咯烷酮1.7份。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010840493.5A CN112014567B (zh) | 2020-08-20 | 2020-08-20 | 超敏c反应蛋白测定试剂盒 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010840493.5A CN112014567B (zh) | 2020-08-20 | 2020-08-20 | 超敏c反应蛋白测定试剂盒 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112014567A CN112014567A (zh) | 2020-12-01 |
| CN112014567B true CN112014567B (zh) | 2023-11-17 |
Family
ID=73505134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010840493.5A Active CN112014567B (zh) | 2020-08-20 | 2020-08-20 | 超敏c反应蛋白测定试剂盒 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112014567B (zh) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103941017A (zh) * | 2014-03-18 | 2014-07-23 | 北京普恩光德生物科技开发有限公司 | C反应蛋白检测试剂盒 |
| CN104381247A (zh) * | 2014-12-02 | 2015-03-04 | 三河市盛繁商贸有限公司 | 猪冷冻精液稀释液的制备方法 |
| WO2017006961A1 (ja) * | 2015-07-06 | 2017-01-12 | 富士フイルム株式会社 | 血液検査キット及び血液分析方法 |
| CN106525552A (zh) * | 2016-11-28 | 2017-03-22 | 天津大学 | 一种血清样品稀释液及检测试剂盒 |
| CN106771253A (zh) * | 2017-01-17 | 2017-05-31 | 安徽同致生物工程股份有限公司 | 肝素结合蛋白测定试剂盒 |
| CN108226498A (zh) * | 2018-01-09 | 2018-06-29 | 郑州安图生物工程股份有限公司 | 一种检测甲胎蛋白异质体afp-（l1+l2）的试剂盒 |
| CN108593907A (zh) * | 2018-05-21 | 2018-09-28 | 苏州佑君环境科技有限公司 | 一种羧基化磁性粒子的稀释液及其制备方法 |
| CN110346443A (zh) * | 2018-04-04 | 2019-10-18 | 内蒙古蒙牛乳业（集团）股份有限公司 | 检测牛乳中A2β-酪蛋白含量的方法 |
| CN110672849A (zh) * | 2019-11-12 | 2020-01-10 | 郑州安图生物工程股份有限公司 | 一种s100蛋白的检测试剂盒 |
| CN111044721A (zh) * | 2020-01-02 | 2020-04-21 | 山东帝俊生物技术有限公司 | 一种利用间接elisa法检测破伤风抗体效价的检测方法 |
| CN111505304A (zh) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | 一种化学发光法检测半乳糖凝集素-3的试剂盒及使用方法 |
-
2020
- 2020-08-20 CN CN202010840493.5A patent/CN112014567B/zh active Active
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103941017A (zh) * | 2014-03-18 | 2014-07-23 | 北京普恩光德生物科技开发有限公司 | C反应蛋白检测试剂盒 |
| CN104381247A (zh) * | 2014-12-02 | 2015-03-04 | 三河市盛繁商贸有限公司 | 猪冷冻精液稀释液的制备方法 |
| WO2017006961A1 (ja) * | 2015-07-06 | 2017-01-12 | 富士フイルム株式会社 | 血液検査キット及び血液分析方法 |
| CN106525552A (zh) * | 2016-11-28 | 2017-03-22 | 天津大学 | 一种血清样品稀释液及检测试剂盒 |
| CN106771253A (zh) * | 2017-01-17 | 2017-05-31 | 安徽同致生物工程股份有限公司 | 肝素结合蛋白测定试剂盒 |
| CN108226498A (zh) * | 2018-01-09 | 2018-06-29 | 郑州安图生物工程股份有限公司 | 一种检测甲胎蛋白异质体afp-（l1+l2）的试剂盒 |
| CN110346443A (zh) * | 2018-04-04 | 2019-10-18 | 内蒙古蒙牛乳业（集团）股份有限公司 | 检测牛乳中A2β-酪蛋白含量的方法 |
| CN108593907A (zh) * | 2018-05-21 | 2018-09-28 | 苏州佑君环境科技有限公司 | 一种羧基化磁性粒子的稀释液及其制备方法 |
| CN111505304A (zh) * | 2019-01-31 | 2020-08-07 | 艾维可生物科技有限公司 | 一种化学发光法检测半乳糖凝集素-3的试剂盒及使用方法 |
| CN110672849A (zh) * | 2019-11-12 | 2020-01-10 | 郑州安图生物工程股份有限公司 | 一种s100蛋白的检测试剂盒 |
| CN111044721A (zh) * | 2020-01-02 | 2020-04-21 | 山东帝俊生物技术有限公司 | 一种利用间接elisa法检测破伤风抗体效价的检测方法 |
Non-Patent Citations (2)
| Title |
|---|
| CRP、超敏CRP联合血常规检测在儿科早期感染性疾病中的应用价值;王佳丽;;医学理论与实践(第01期);全文 * |
| 定量检测人超敏C-反应蛋白双抗体夹心ELISA方法的建立及初步临床应用;沈丹丹;卞智萍;何国平;顾春荣;徐晋妉;杨笛;张寄南;;中国临床药理学与治疗学(第01期);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112014567A (zh) | 2020-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Endo et al. | Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study | |
| JP6941324B2 (ja) | 新規な肝硬変または肝線維症のマーカー | |
| Li et al. | Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-β in human glioma cells | |
| CN108956978A (zh) | 一种应用胶乳免疫比浊法的肝素结合蛋白测定试剂盒及测定方法 | |
| Lo Re et al. | Obesity-induced nucleosome release predicts poor cardio-metabolic health | |
| CN112014567B (zh) | 超敏c反应蛋白测定试剂盒 | |
| Mahmoodi et al. | Determination of serum survivin for prognostic role in esophageal cancer | |
| Liu et al. | Value of dynamic plasma cell-free DNA monitoring in septic shock syndrome: A case report | |
| RU2379684C2 (ru) | Способ определения антитромботического эффекта ацетилсалициловой кислоты | |
| Agrup et al. | 5-S-cysteinyldopa in the urine of melanoma patients | |
| JP7081861B1 (ja) | ＬＩＰに基づいてＵＭＯＤを修飾した尿中のＮｅｕ５Ｇｃを識別する尿路上皮癌の検査用キット、およびその製造方法 | |
| CN114113631B (zh) | 脓毒症的检测试剂盒 | |
| CN108344875B (zh) | 提高活化部分凝血活酶时间试剂对肝素敏感性的方法及用途 | |
| CN115710313A (zh) | 用于检测γ干扰素的抗体组合及其应用 | |
| Upton et al. | (1→ 3) β-d-glucan assay in the diagnosis of invasive fungal infections | |
| RU2683955C1 (ru) | Способ ранней дифференциальной диагностики геморрагической лихорадки с почечным синдромом | |
| CN111537719A (zh) | 血清Sparcl1蛋白在非酒精性脂肪性肝炎诊断中的应用 | |
| Zhang | Determination of Pasma Procalcitonin and Its Application in Sepsis Infection | |
| Zou et al. | A Primary Cardiac Osteosarcoma: Case Report and Literature Review | |
| CN113652479B (zh) | 基于分子标志物的冠状动脉疾病诊断产品及其应用 | |
| CN110187100B (zh) | Prokineticin2在制备脓毒症诊断试剂、治疗药物中的用途 | |
| RU2111495C1 (ru) | Способ диагностики злокачественной опухоли | |
| Yang et al. | The Role of Gold Nanorods in Detecting Circulating microRNAs as Biomarkers in Liver Diseases | |
| Najm et al. | Study of procalcitonin and neutrophil/lymphocyte count ratio in children infected with Community-acquired pneumonia | |
| RU2618401C1 (ru) | Способ диагностики хронического панкреатита алкогольной этиологии |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |